FM-101 is under clinical development by Future Medicine and currently in Phase I for Primary Biliary Cholangitis (Primary Biliary Cirrhosis). According to GlobalData, Phase I drugs for Primary Biliary Cholangitis (Primary Biliary Cirrhosis) have a 93% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how FM-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
FM-101 overview
FM-101 is under development for the treatment of ocular hypertension, diabetic nephropathy, non-alcoholic fatty liver disease, primary biliary cholangitis, glaucoma and non-alcoholic steatohepatitis. The drug candidate is a nucleoside derivative. It is administered through oral route. It acts by targeting A3 adenosine receptor. The drug candidate is being developed based on Future Medicine Origin Compound Library Universal System (FOCUS) platform.
The drug candidate was under development for chronic kidney disease.
Future Medicine overview
Future Medicine is a company that develops drugs using a nucleoside library platform. The company is headquartered in Seongnam, Gyeonggi-do, Republic of Korea (South Korea).
For a complete picture of FM-101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
